BRD4 and cancer: Of note, according to The Cancer Genome Atlas database, BRD4 gene is amplified in approximately 10% of HGSOCs, laying the groundwork for BETis to represent a potentially effective therapeutic strategy in this subtype of tumors with poor clinical outcome.